Virus Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 143 trials

Recruiting
Not Applicable

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

Cervical CarcinomaHuman Papillomavirus Infection
National Cancer Institute (NCI)750 enrolled14 locationsNCT06498661
Recruiting

The Role of Circulating Tumour DNA in Head and Neck Cancer

Oropharyngeal Squamous Cell CarcinomaHuman Papillomavirus (HPV)
University of Edinburgh250 enrolled5 locationsNCT05539638
Recruiting
Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled27 locationsNCT07071623
Recruiting
Phase 2

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618
Recruiting
Not Applicable

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

HIV (Human Immunodeficiency Virus)
University of California, San Francisco33 enrolled1 locationNCT07115901
Recruiting
Not Applicable

Improving Access to HIV Testing for Children in Uganda

HIV (Human Immunodeficiency Virus)
University of California, San Francisco400 enrolled1 locationNCT07236905
Recruiting
Not Applicable

California MEPS Hub

Substance Use Disorder (SUD)HIV PreventionHepatitis C Virus (HCV)+3 more
University of California, Los Angeles318 enrolled3 locationsNCT07433985
Recruiting
Not Applicable

Point of Care - Triage and Treatment for Cervical Pre-cancer

Cervical Intraepithelial NeoplasiaHuman Papillomavirus InfectionCervical Precancer
Basic Health International, Inc.5,000 enrolled1 locationNCT07461818
Recruiting
Phase 2

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Head and Neck CancerLaryngeal CancerOral Cavity Cancer+6 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins75 enrolled1 locationNCT07209189
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled70 locationsNCT07044297
Recruiting
Phase 2

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Oropharyngeal CancerThroat CancerHuman Papilloma Virus+2 more
Memorial Sloan Kettering Cancer Center121 enrolled7 locationsNCT05491512
Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting
Phase 2

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Jennifer Crombie, MD35 enrolled2 locationsNCT05934448
Recruiting
Phase 1Phase 2

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaHuman Papilloma Virus+1 more
University of Chicago98 enrolled1 locationNCT05108870
Recruiting
Phase 1Phase 2

EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

Epstein-Barr Virus-Associated Lymphoproliferative DisordersEBV-Positive Lymphoma
Daihong Liu18 enrolled1 locationNCT07450391
Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled24 locationsNCT07266831
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 4

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)Human Papillomavirus (HPV) InfectionsHigh-risk HPV+1 more
Miquel Angel Pavon Ribas69 enrolled1 locationNCT05334706